Covid-19 Mrna (Pfizer) Vaccine Dosage

Medically reviewed by Drugs.com. Last updated on Sep 17, 2024.

Usual Adult Dose for COVID-19

GRAY LABEL: 0.3 mL IM ONCE, at least 2 months after receiving the last previous dose of COVID-19 vaccine

Comments:

• Each 0.3 mL dose of the gray labeled syringe contains 30 mcg of a nucleoside-modified messenger RNA encoding the viral spike (S) glycoprotein of SARS-CoV-2 Omicron variant sublineage LP.8.1.
• For additional information: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

Uses:

• Active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients 18 to 64 years of age with at least 1 underlying condition that puts them at high-risk for severe outcomes from COVID-19
• Active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients 65 years and older

Usual Pediatric Dose for COVID-19

5 to 11 years:

• BLUE CAP/LABEL: 0.3 mL IM ONCE, at least 2 months after receiving the last previous dose of COVID-19 vaccine

12 years and older:

• GRAY LABEL: 0.3 mL IM ONCE, at least 2 months after receiving the last previous dose of COVID-19 vaccine

Comments:

• Each 0.3 mL dose of the blue capped and labeled single-dose vial contains 10 mcg of a nucleoside-modified messenger RNA encoding the viral spike (S) glycoprotein of SARS-CoV-2 Omicron variant sublineage LP.8.1.
• Each 0.3 mL dose of the gray labeled syringe contains 30 mcg of a nucleoside-modified messenger RNA encoding the viral spike (S) glycoprotein of SARS-CoV-2 Omicron variant sublineage LP.8.1.
• For additional information: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

Use: Active immunization to prevent COVID-19 caused by SARS-CoV-2 in patients 5 to 18 years of age with at least 1 underlying condition that puts them at high-risk for severe outcomes from COVID-19

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Patients with a known history of severe allergic reaction to the active component or any of the ingredients
• Patients with a severe allergic reaction (e.g., anaphylaxis) following administration of a COVID-19 vaccine

Safety and efficacy have not been established in patients younger than 5 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• For IM administration only. Do not inject IV, intradermally, or subcutaneously.
• Single-dose vial: Invert the vial gently 10 times before withdrawing the dose; do not shake.
• Prefilled syringe: Do not shake syringe; attach a sterile needle prior to administration.

Storage requirements:

• During storage, minimize exposure to room light and avoid exposure to direct sunlight and ultraviolet light.
• Prefilled syringe:
• Do not freeze; discard if product has been frozen.
• If prepared syringes are not used immediately, they must be used within 4 hours of attachment with a sterile needle.
• The total time that syringes may remain unrefrigerated at temperatures between 8C and 25C (46F and 77F) should not exceed 12 hours.

• Single-dose vial storage before use: Consult the manufacturer product information and/or the Fact Sheet for Health Care Providers.
• If frozen, thaw in the refrigerator 2C to 8C (35F to 46F) for up to 2 hours OR at room temperature up to 25C (77F) for up to 30 minutes; the total time that vials may remain unrefrigerated at temperatures between 8C and 25C (46F and 77F) must not exceed 12 hours.
• Store refrigerated between 2C and 8C (36F and 46F) for up to 10 weeks.
• Once withdrawn from the vial, the dose should be immediately administered.
• Do not refreeze thawed vials.

Reconstitution/preparation techniques:

• Vials and prefilled syringes should not be diluted prior to use.
• The manufacturer product information should be consulted.

General:

• Pediatric vaccine products are supplied in a single-dose vial with a blue cap and a blue label border stating "2025-2026 Formula;" adult vaccine products are supplied as prefilled syringes with a gray label border stating "2025-2026 Formula."
• Each dose must contain 0.3 mL of vaccine.
• This vaccine does not contain preservatives.

Patient advice:

• To report suspected adverse reactions, contact the Vaccine Adverse Event Reporting System (VAERS): https://vaers.hhs.gov

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer